• SPX
  • $5,977.41
  • -0.13 %
  • -$7.97
  • DJI
  • $43,954.94
  • -0.01 %
  • -$3.26
  • N225
  • $38,535.70
  • -0.48 %
  • -$185.96
  • FTSE
  • $8,068.16
  • 0.47 %
  • $37.83
  • IXIC
  • $19,200.07
  • -0.16 %
  • -$30.67
NLS Pharmaceutics AG (NLSPW) Stock Price, News & Analysis

NLS Pharmaceutics AG (NLSPW) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.02

$0.01

(65.38%)

Day's range
$0.02
Day's range
$0.02
50-day range
$0.0071
Day's range
$0.022
  • Country: CH
  • ISIN: CH0573155204
52 wk range
$0.01
Day's range
$0.17
  • CEO: Mr. Alexander Zwyer M.B.A.
  • Website: N/A


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -150.85
  • Piotroski Score 1.00
  • Grade N/A
  • Symbol (NLSPW)
  • Company NLS Pharmaceutics AG
  • Price $0.02
  • Changes Percentage (65.38%)
  • Change $0.01
  • Day Low $0.02
  • Day High $0.02
  • Year High $0.17

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) N/A
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.00
  • Trailing P/E Ratio N/A
  • Forward P/E Ratio N/A
  • P/E Growth N/A
  • Net Income $-12,172,029

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.